ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
Humanized PMN310 and Aducanumab Show Similar Ability to Cross the Blood Brain Barrier in Aged Mice. TORONTO and CAMBRIDGE, MA, March 6, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery […]